Introduction
was already high in COPD patient than normal. To identify the regulatory sequence in 3'-150 UTR of TRPC6, full length and additional two reporters with truncated sequence in 3'-UTR 151 of TRPC6 were established. A computational search predicted the site of miR-135a/b-5p 152 binding to the TRPC6-3' UTR ( Fig. 2G) . HASMCs infected with lentivirus of miR-135a/b-153 5p were transfected with pmiR-TRPC6-3'UTR-FL or TRPC6-3'UTR truncates respectively, 154 luciferase reporter activity of TRPC6-3'UTR-FL and TRPC6-3'UTR-1-49 were decreased, 155 the empty vector and TRPC6-3'UTR-1-43 did not ( Fig. 2H) , suggesting the sequence from 156 43-49 of 3'UTR of TRPC6 was essential to bind between miR-135a/b-5p and TRPC6 mRNA. 157 In addition, decreased level of the miR-135a/b-5p by nicotine ( Fig. 2I) can further increase 158 TRPC6 expression. These lines of evidence collectively demonstrated that miR-135a/b-5p 159 recognized and regulated TRPC6 mRNA through specific binding to its 3' UTR. If the miR-160 135a/b-5p binding with TRPC6 mRNA degraded TRPC6 mRNA, down-regulation of miR-161 135a/b-5p in COPD might also enhance TRPC6 expression. As determined by real-time PCR 162 analysis of the expression levels of miR-135a/b-5p and TRPC6 mRNA, a significant negative 163 correlation between the miR-135a/b-5p and TRPC6 mRNA was identified in normal and 164 COPD bronchial smooth muscle samples ( Fig. 2J) , suggesting a protective role of miR-165 135a/b-5p in the occurrence and development of COPD through targeting and degrading 166 TRPC6 mRNA. To study the effect of miR-135a/b-5p and TRPC6 on HASMCs migration, 167 normal and COPD HASMCs were infected with lentivirus of miR-135a/b-5p and treated with 168 SAR 7334. COPD HASMCs migrated faster than normal, miR-135a/b-5p and inhibitor of 169 TRPC6 abolished this increase ( Fig. 2K and Sup. Fig. 2) . 170 Nicotine promotes NF-κB translocation and increases NF-κB transcriptional activity 171 through α7 nAChR in a ROS-dependent manner. 172 To understand the molecular profiling of HASMCs responding to nicotine stimulation, a 173 genome-wide unbiased approach to analyze gene expression by RNA sequencing was 174 performed. Gene set enrichment analysis (GSEA) analysis of the whole transcriptome using 175 the curated gene set compilation "BIOCARTA" revealed a profound impact on gene 176 expression networks. Enrichment in gene sets corresponding to 177 ''BIOCARTA_NFKB_PATHWAY'' and ''BIOCARTA_NFAT_PATHWAY'', are the top 178 enriched signatures (Fig. 3A) . These results indicate that NF-κB signaling genes and 179 signaling genes were upregulated upon nicotine treatment in HASMCs. To further explore 180 the effect of nicotine on NF-κB activation, normal HASMCs were treated with nicotine in an 181 increasing concentration manner. Whereas nicotine treatment resulted in nuclear 182 accumulation of NF-κB and reduced cytoplasmic NF-κB ( Fig. 3B) . Normal HASMCs were 183 exposed to nicotine or PBS for 24hours, then cytosol were extracted and subjected to co-184 immunoprecipitation studies to evaluate the effect of nicotine to the protein-protein 185 interactions between IκBα and NF-κB. The IκBα and NF-κB protein-protein interaction was 186 weakened by nicotine treatment (Fig. 3C) . These results supported the notion of promotional 187 effects of nicotine on NF-κB translocation. Previous studies have revealed that the 188 mitochondrial complex I inhibitor rotenone and the complex III preubisemiquinone site 189 inhibitor myxothiazol block the hypoxia-induced increase in [ROS] (Fig. 3D) . Our data indicates that 197 the mean increase in DCF fluorescence after nicotine stimulation was not significantly lower 198 in cells treated with either rotenone (10 μM) or myxothiazol (10 μM) for 30 min compared to 199 cells treated with PBS ( Fig. 3D) . Whereas, nicotine activates NF-κB activity, however, this 200 increase was abolished by N-acetyl-cysteine (NAC) commonly used to inhibit ROS and MG 201 624 (inhibitor of α7 nAChR) ( Fig. 3E and 3F) . Taken together, we conclude nicotine 202 activates NF-κB transcriptionally activity through α7 nAChR in an ROS-dependent manner 203 in HASMCs.
204
Nicotine increases TRPC6 channel expression and activity through NF-κB. 205 To determine the possibility of the NF-κB binding site for TRPC6 expression, we employed a 206 luciferase reporter construct driven by the TRPC6 promoter sequence. Plasmids were 207 transfected into the normal HASMCs and luciferase activity assays were performed.
208
Manipulation of the nicotine and NF-κB positively correlates with cellular TRPC6 209 transcriptional activity ( Fig. 4A) . TRPC6 mRNA expression level was increased by nicotine 210 in HASMCs, however, NF-κB_sh, and BAY 11-7082 abolished nicotine caused TRPC6 211 mRNA expression increase (Fig. 4B) . HASMCs infected with lentivirus of p65_sh and 212 p50_sh (NF-κB_sh) were followed by stimulation with nicotine. As expected, TRPC6 protein 213 level did not significantly change in the knockdown of NF-κB group (Fig. 4C) protein expression in an NF-κB dependent mechanism. We performed EMSA to further 219 verify the putative interaction between NF-κB and NF-κB response element (NRE) of 220 TRPC6 promoter. In the probe-shift assays, increasing exposure hours of nicotine was shown 221 to significantly increase the intensity of the shifted band ( Fig. 4E) . In the supershift assays 222 ( Fig. 4F) , incubation of p65 antibody with HASMCs nuclear extract pre-incubated with 223 biotin-labeled wild-type probe led to the formation of a supershifted band with larger 224 molecular weight than the shifted band, suggesting the formation of an NRE-WT/p65/anti-225 p65 antibody complex. In addition, pre-incubation of nuclear extract with a 200-fold excess 226 of unlabeled WT probe completely diminished the shifted band, whereas a 200-fold excess of 227 unlabeled mutant probe failed to do so (Sup. Fig. 3A) . Moreover, incubation of nuclear 228 extract with biotin-labeled mutant probe (NRE-MT) did not result in any shifted band (Sup. 229 Fig. 3B ). Furthermore, pre-incubation of nuclear extract with biotin-labeled MT probe did 230 not prevent the formation of the shifted band after subsequent incubation with biotin-labeled 231 WT probe. Together, these data clearly demonstrated the interaction of NF-κB with NRE-WT 232 in TRPC6 promoter in HASMCs.
233

Cigarette smoke causes ASM hyperresponsiveness and remodeling in mice model and
234
NFAT signaling activation in Mouse Airway Smooth Muscle Cells (MASMCs).
235
Inhalation of cigarette smoke enhanced methacholine-induced increase of airway resistance 236 and contraction, tail vein injection of lentivirus of SMC specific TRPC6_shRNAs abolished 237 this enhancement in mice with cigarette-evoked airway disease ( Fig. 5A and 5B) . To assess 238 the downstream pathway responding to TRPC6 altered [Ca 2+ ] i in the regulation of 239 proliferation, we measured the expression of NFAT and its target genes. Cigarette smoke 240 could result in a significant increase in NFAT and its targets gene we examined, however, Ki67-positive cells) was eliminated by tail vein injection of lentivirus of SMC specific 246 TRPC6_shRNAs ( Fig. 5D and 5E) . Taken together, lentivirus of SMC specific 247 TRPC6_shRNAs can specifically knockdown the TRPC6 protein in ASMCs, thereby block 248 cigarette induced airway hyper-responsiveness and re-modelling. Taking these data together, 249 we proposed that cigarette smoke through TRPC6 could determine the selection of NFAT-250 mediated cell cycle. and cigarette evoked airway disease, evidenced by the absence of the enhanced 259 methacholine-induced increase in airway resistance and contraction ( Fig. 6A and 6B) . 260 Ovalbumin treated mice also exhibited a large increase in ASM mass and HASMCs the percentage of TRPC6 protein positive cells was much higher in COPD than normal 272 samples ( Fig. 7B) . Correlation study showed TRPC6 protein expression was proportional 273 with the bronchial smooth muscle layer thickness (pink) (Sup. Fig. 6 ). Therefore, mapping the molecular mechanisms for nicotine induced alterations in bronchial 285 smooth muscle cells may offer clues into COPD pathogenesis and treatment. TRPC6 is 286 highly expressed in smooth muscle as well as in brain and cardiomyocytes. But few 287 physiological roles have been correlated with its expression. In this regard, we found 288 increased expression of TRPC6 and decreased miR-135a/b-5p in ASM tissue of bronchial 289 obtained from humans with COPD. Furthermore, even though there was an inter-individual 290 variation for miR-135a/b-5p and TRPC6 expression across our sample set, we were also able 291 to demonstrate a significantly inverse correlation existed between these two measurements in 292 normal and COPD bronchial smooth muscle tissue, suggesting that TRPC6 channel 293 expression was downregulated by miR-135a/b-5p in vivo as well. To date, however, given the 294 relative lack of research on miR-135a/b-5p in human smooth muscle disease, we wished to 295 investigate its functionality further by investigating how miR-135a/b-5p acts upon other 296 targets might contribute to the disruption of normal molecular pathways in COPD. Our study 297 is the first to show that miR-135a/b-5p expression is downregulated in a panel of bronchial 298 smooth muscle tissue of COPD patients in comparison with normal donor. Our in vitro assays 299 showed that over-expression of miR-135a/b-5p inhibited proliferation and migration of 300 HASMCs. We therefore conclude that miR-135a/b-5p can suppress proliferation in HASMCs.
301
Although several targets of miR-135a/b-5p have been biologically verified 35 36 , none has 302 been proven in HASMCs. This is also the first study to show that TRPC6 is regulated by 303 miR-135a/b-5p in HASMCs. More supporting evidence point out that miR-135a/b-5p 304 expression inversely correlated with TRPC6 levels, which suggested that miR-135a/b-5p 305 could be an important genetic marker for this disease. We propose that stratifying patients 306 into groups which show high or low miR-135a/b-5p levels could be a useful tool to identify 307 low-and high-risk for COPD progression, as others have done for miR-135a/b-5p expression 308 in bladder cancer 37 , oral carcinoma 38 , lung cancer 39 , colorectal cancer 40 , and acute 309 leukemia 41 . We therefore conclude that miR-135a/b-5p is one of the factors contributing to 310 the regulation of TRPC6 expression in COPD and may explain why altered expression of 311 miR-135a/b-5p has been reported in COPD. This is significant because it means miR-135a/b-312 5p plays an integral role in control of cell proliferation and its aberrant expression is therefore 313 likely to disrupt normal cell growth. However, the effect of miR-135a/b-5p on TRPC6 alone 314 is not likely fully explain the phenotypic effects observed and it is worth remembering that 315 miR-135a/b-5p will undoubtedly exert an effect on several other targets that control cell 316 growth as well. It is important to emphasize that it is the precise balance of the interactions 317 discussed here, which will determine the overall functionality of miR-135a/b-5p in the cell 318 and explains the apparent ability of miR-135a/b-5p to act in contrasting fashions in different 319 disease.
320
Overall, the results presented here describe a novel pathway for HASMCs exposed to 321 nicotine in promoting proliferation through nicotine →α7 nAChR→ROS→NF-322 κB→TRPC6→NFAT signaling which have not been reported previously (Fig. 7C) . We 323 propose a model in which nicotine, via NF-κB and miR-135a/b-5p, enhances expression and 324 activation of TRPC6 in ASM, leading to a phenotype switch from a contractile/quiescent to a 325 synthetic/proliferative type. 337 The authors declare that they have no competing interests. (5) were transfected with NF-κB luciferase reporter plasmid and exposed to nicotine (1µM) 560 and different inhibitors as indicated. NF-κB reporter assays were performed after these 561 treatments. Firefly luciferase expression was normalized to renilla luciferase.
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Experiments were repeated in three independent groups. *, p<0.05; **, p<0.01 compared 563 with nicotine (0%) group. ##, p<0.01 compared with control group. C. NF-κB knockdown attenuated nicotine-induced TRPC6 protein increase in HASMCs.
585
Normal HASMCs infected with lentivirus of p65_SH, p50_SH or control_SH were 586 followed by stimulation with nicotine (1µM) as indicated hours. Protein expression of 587 TRPC6, p65, p50 and GAPDH were determined by immunoblotting, experiment was 588 repeated in three independent groups. 589 D. Inhibition of NF-κB abolished nicotine-induced TRPC6 protein increase in HASMCs.
590
Normal HASMCs were pre-treated with the NF-κB inhibitor BAY 11-7082 (10 μM) and 591 PBS as vehicle for 2 hours, followed by stimulation with nicotine (1µM) as indicated 592 hours, TRPC6 and GAPDH were determined by immunoblotting. 
